Kura Oncology, Inc 10-Q for FY2026 Q3
Kura Oncology, Inc. (KURA)
10-Q
2026-11-10
For: 2026-09-30
View Original
Added on
November 10, 2026
About this 10-Q
Kura Oncology, Inc filed this 10-Q on November 10, 2026, covering the quarter ended September 30, 2026 (FY2026 Q3).
Kura Oncology reported $28.8 million in KOMZIFTI net product revenue for the nine months ended September 30, 2026. Cash, cash equivalents and short-term investments totaled $492.1 million as of September 30, 2026. AI summary
Headline figures
Quarter ended September 30, 2026, as reported in this filing, compared with the same period a year earlier where the filing states it.
- Revenue
- $22.84M
- up 10.1% from $20.75M a year earlier
- Net loss
- $70.22M
- compared with a net loss of $74.12M a year earlier
- Diluted EPS
- -$0.78
- compared with -$0.85 a year earlier